UK markets closed

IMV Inc. (IMV)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.3800-0.0600 (-1.74%)
At close: 4:00PM EDT
Sign in to post a message.
  • B
    BEL
    Really baffled... small tiny pharma companies in USA jump from cents to dollars on trivial news.. while this company getting funding( good sign) and starting phase1-2 together and still goes down.. I think it is manipulated to be down..just my opinion
  • Y
    Yesman
    Selected for additional funding by Canadian Government bringing total support to $10M for clinical development and manufacturing of DPX-COVID-19

    Clinical plan updated to run a larger Phase 1/2 study with the goal to expedite later-stage development

    Collaboration initiated with a global manufacturing partner to develop and expand manufacturing capacity up to several hundred million of doses.

    https://www.imv-inc.com/news-events/press-releases/detail/661/imv-provides-updates-on-covid-19-vaccine-program
    IMV Provides Updates On COVID-19 Vaccine Program
    www.imv-inc.com
  • T
    Tony
    • November 9 - 8.00am EST: Full abstract will be released on the SITC meeting platform,
    • November 11 - 9.00am EST: Poster will be posted on Company’s website and poster presentation will be available on the SITC conference platform,
    • November 12 – 8.00am EST: Company will discuss data during a live webcast,
    • November 12 from 4.50-5.20pm EST and November 14 from 1.00-1.30pm EST, a Q&A session will be held on the SITC meeting platform.
  • R
    Robert
    their website says cold vaccine is about to go into phase 1 trials.
  • Y
    Yesman
    Very Bullish news, don't understand why this stock is not + $10
  • s
    sam
    What’s the word over here ? To me Sounds like a good company to invest.
  • R
    Robert
    this is about to break to the upside.
  • H
    Hawk
    Why does this keep going up... just had to change prior post...
  • M
    Mujtaba
    Is there any expected date coming up that could potentially impact the price for this?
  • T
    Tony
    IMV CEO to Participate at the Vaccines Panel of the Sachs Associates 20th Annual Biotech in Europe Forum Sept 21-24
  • S
    Sebastien
    Why is this dropping ?
  • J
    Jeffrey
    Initiation of clinic trials and publications of preclinical results Summer 2020, hope IMV knows the last day of Summer 2020 is Monday, September 21st! I believe, a big portion of my portfolio is counting on you IMV.
  • C
    Crow
    Anybody know of a particular reason for yesterdays run up?
  • D
    Daniel
    expecting good phase 1 results?
  • K
    Khan
    when is IMV releasing testing results?
  • V
    V
    a little rally here, please tell me this will surge past $6 USD soon!
  • K
    Khan
    What is the reason for drop today?
  • M
    Mujtaba
    The report sounded positive enough. Why is this taking such a fall?
  • W
    William
    Good News!!
    IMV today announced that Canadian government agencies will contribute up to
    CA$4.75 mln to advance Phase 1 clinical development of its vaccine candidate,
    DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel
    coronavirus SARS-COV-2.
    The company is receiving CA$4.15 mln advisory services and funding from the
    National Research Council of Canada Industrial Research Assistance Program,
    Atlantic Canada Opportunities Agency, and Next Generation Manufacturing Canada to
    support rapid scale-up of DPX-COVID-19 manufacturing process and its evaluation in
    a phase 1 clinical trial. In addition to this funding, IMV also received CA$600,000 from
    the NRC IRAP Innovation Assistance Program.
    IMV plans to use funding from to advance DPX-COVID-19 with a Phase I clinical trial
    starting this summer in Canada. A Phase 2 trial is expected to start by end of 2020 in
    the US and Canada following successful Phase 1 top-line results that are expected
    later this year. Funding will also support the cale-up manufacturing capacity for
    commercial production for North American and global markets.